US 12,337,024 · Application 17/635,441 · Granted Jun 24, 2025
US 12,337,024
Larazotide formulations
Estimated expiration
December 25, 2040
14y 90d remaining
Earliest effective filing
Aug 14, 2020
+ 20 years
Aug 14, 2040
PTA +133d
Dec 25, 2040
No TD
—
Final
Dec 25, 2040
This calculation includes patent term adjustment (PTA) under 35 U.S.C. §154(b). Patent term extension (PTE) under 35 U.S.C. §156 (for FDA-regulated products) is not included.
Calculation details
Base term
- Filing date
- February 15, 2022
- Earliest effective filing
- August 14, 2020
- Issue date
- June 24, 2025
- PTA
- +133 days
- Base expiry (before PTA)
- August 14, 2040
August 14, 2020 + 20 years = August 14, 2040 + 133 PTA days = December 25, 2040
- National stage entry of application PCTUS2020046272, filed Aug 14, 2020
- PRO63/009,768 — Provisional — not used for base term
- PRO62/888,052 — Provisional — not used for base term
- PRO63/009,768 — Provisional — not used for base term
- PRO62/888,052 — Provisional — not used for base term
Terminal disclaimers
Patent term extension under 35 U.S.C. §156, which can apply to certain drug, biologic, animal drug and medical device patents, is not included in this calculation. How PTE is calculated
The prosecution record for your AI
Application 17/635,441 · US 12,337,024
You have the date. Your AI can have the file.
PatentReply compiles the prosecution history behind US 12,337,024: the claims as filed and as allowed, every Office Action and response, and the cited references, with each answer pointing back to the filed passage.
One new public application a month is free. The first compile takes a few minutes.
Strategy and filing changes require your approval.
Permanent link
www.patentreply.ai/tools/patent-expiration/US12337024Data sourced from public USPTO records. This tool provides informational estimates and should not be relied upon as legal advice. Always verify patent expiration dates independently, especially where patent term extension, terminal disclaimers, or unusual continuity issues may apply.